☆ 4.6 Article

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC

JOURNAL OF THORACIC ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden A Nonrandomized Controlled Trial

Mariano Provencio et al.

Summary: The study assessed the clinical benefits and safety of atezolizumab plus bevacizumab for patients with high-TMB nonsquamous NSCLC. The results showed that this combination therapy has the potential to be a treatment option for high-TMB nonsquamous NSCLC.

JAMA ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Joao V. Alessi et al.

Summary: The efficacy of chemoimmunotherapy (CIT) in advanced NSCLC is associated with factors such as performance status, neutrophil-to-lymphocyte ratio, PD-L1 expression, and tumor mutational burden.

JOURNAL OF THORACIC ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

L. E. Hendriks et al.

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

T. S. K. Mok et al.

Summary: This study evaluated the clinical utility of tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in PD-L1-positive advanced/metastatic non-small-cell lung cancer (NSCLC) patients. It suggests that tTMB could be a potential predictive biomarker for pembrolizumab monotherapy in NSCLC, and pembrolizumab is a standard first-line treatment regardless of STK11, KEAP1, or KRAS mutation status.

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

D. Boiarsky et al.

Summary: This study analyzed clinicogenomic data from 1817 patients with KRAS-mutant lung adenocarcinoma and found that mutations in KEAP1 and SMARCA4 genes were associated with metastatic disease and poor overall survival. Functional loss of STK11 gene may contribute to poor outcomes in KEAP1-mutated tumors.

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Namrata S. Patil et al.

Summary: The study revealed that inhibitors of the PD-1/PD-L1 signaling axis have a significant overall survival benefit for non-small cell lung cancer (NSCLC) patients. Transcriptomic analysis and single-cell RNA sequencing showed that B and plasma cells play an important role in the efficacy of PD-L1 blockade in NSCLC.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti et al.

Summary: STK11 and KEAP1 mutations have a negative impact on the efficacy of immunotherapy in lung adenocarcinoma, but this effect is only observed in KRAS-positive tumors. Tumors with concurrent KRAS/STK11 and KRAS/KEAP1 mutations exhibit distinct immune characteristics.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Review Immunology

Targeting STING for cancer immunotherapy: From mechanisms to translation

Ruilei Huang et al.

Summary: This article reviews the role of the STING signaling pathway and its involvement in different stages of the cancer immunity cycle. It also discusses the development and challenges of STING agonists, with the aim of enhancing the effectiveness of cancer immunotherapy with STING agonists.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

添加到收藏夹

Article Oncology

Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes

Aleksandr Zaitsev et al.

Summary: Cellular deconvolution algorithms analyze gene expression to reconstruct tissue composition. The Kassandra algorithm, a decision tree machine learning algorithm, accurately reconstructs the tumor microenvironment (TME). It shows stability and robustness, and accurately deconvolves TME elements.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Leveraging big data of immune checkpoint blockade response identifies novel potential targets

Y. Bareche et al.

Summary: This study conducted a comparative meta-analysis of genomic and transcriptomic biomarkers of immune checkpoint blockade (ICB) responses, revealing that tumor mutational burden (TMB) and 21 out of 37 gene signatures predicted ICB responses across different tumor types. A new GE signature called Predict$O was developed, showing superior predictive value over other biomarkers. Additionally, two genes F2RL1 and RBFOX2 were associated with poor clinical outcomes, T-cell dysfunction in ICB-naive patients, and resistance to dual PD-1/CTLA-4 blockade in preclinical models.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

Shunsuke Kitajima et al.

Summary: KRAS-LKB1 mutant lung cancers silence the STING pathway and minimize intracellular accumulation of 2'3'-cGAMP to avoid T cell infiltration and decrease response to PD-1 blockade. However, transient MPS1 inhibition can re-activate the STING pathway in KL cells and restore T cell infiltration, enhancing the efficacy of anti-PD-1 treatment.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer

Pietro Rosellini et al.

Summary: STK11 mutation is associated with poor prognosis in non-small cell lung cancer (NSCLC), leading to decreased response to immunotherapy treatment.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC

S. Peters et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Article Multidisciplinary Sciences

RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma

Philip East et al.

Summary: The study found that 84% of patients with lung adenocarcinoma have oncogenic activation of the RAS signaling pathway, with a high proportion of activation even in KRAS wild-type tumors; patient groups with high RAS activity show adverse clinical outcomes and reduced response to chemotherapy. Stratifying patients based on oncogenic RAS transcriptional activity may ultimately assist in clinical decision-making.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Meeting Abstract Oncology

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

S. S. Ramalingam et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Caicun Zhou et al.

Summary: The combination of apatinib and camrelizumab demonstrated promising antitumor activity and manageable toxicity in chemotherapy-pretreated patients with advanced nonsquamous NSCLC. Patients with STK11/KEAP1 mutations may derive greater benefits from this combination therapy. Further validation of these results is ongoing in a phase III trial (NCT04203485).

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?

Alessandro Di Federico et al.

Summary: Immune checkpoint inhibitors (ICIs) are essential in treating advanced non-small cell lung cancer (NSCLC), with PD-L1 expression as the current biomarker for predicting response. STK11/LKB1 and KEAP1 mutations are associated with poor outcomes in NSCLC patients receiving ICI, especially in the presence of concurrent KRAS mutations.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation

Wei Nie et al.

Summary: Somatic mutations of STK11 or KEAP1 in aNSCLC patients are associated with poor clinical outcomes when receiving different treatments. This study compared the efficacy of atezolizumab versus docetaxel in SKmut aNSCLC patients, showing that atezolizumab was associated with significantly longer overall survival compared to docetaxel. Furthermore, patients with FAT3 mutation or high TMB and PD-L1 expression may predict favorable response to atezolizumab treatment.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Pan-cancer single cell landscape of tumor-infiltrating T cells

Liangtao Zheng et al.

Summary: This study constructed a pan-cancer atlas of T cells across 21 cancer types, revealing different composition patterns and state-transition paths of T cells. The correlation between certain T cell populations and patient characteristics sheds light on possible determinants of the tumor microenvironment, providing new insights into T cell immunity and precision immunotherapy.

SCIENCE (2021)

添加到收藏夹

Review Oncology

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker

Elena Fountzilas et al.

Summary: The development of checkpoint blockade immunotherapy has had a positive impact on clinical outcomes, but some patients show resistance and experience serious immune-related adverse events. Understanding the molecular mechanisms and identifying the drivers of therapeutic response and resistance is crucial in optimizing precision immunotherapy.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Oncology

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Nabendu Pore et al.

Summary: Mutations in the STK11 gene can regulate resistance to PD-1/PD-L1 blockade in patients with nonsquamous non-small cell lung cancer. These mutations may lead to resistance to checkpoint blockade by affecting immune phenotype and immune checkpoints. Modulation of STAT3 signaling can reverse this resistance, suggesting potential combination therapies for STK11-mutant NSCLC.

CANCER DISCOVERY (2021)

添加到收藏夹

Letter Respiratory System

Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient

I. Domingues et al.

PULMONOLOGY (2020)

添加到收藏夹

Article Oncology

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

Carminia M. Della Corte et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Review Cell Biology

Molecular mechanisms and cellular functions of cGAS-STING signalling

Karl-Peter Hopfner et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Michael A. Gillette et al.

CELL (2020)

添加到收藏夹

Article Oncology

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

D. Marinelli et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an STK11/LKB1 Mutation

Ernest Nadal et al.

JCO PRECISION ONCOLOGY (2020)

添加到收藏夹

Review Chemistry, Medicinal

Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment

Cristina Borzi et al.

PHARMACEUTICALS (2020)

添加到收藏夹

Article Oncology

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort

Simon Papillon-Cavanagh et al.

ESMO OPEN (2020)

添加到收藏夹

Article Oncology

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

Arnaud Jeanson et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Immunology

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Brian C. Miller et al.

NATURE IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer

Wenfeng Fang et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Benchmark and integration of resources for the estimation of human transcription factor activities

Luz Garcia-Alonso et al.

GENOME RESEARCH (2019)

添加到收藏夹

Meeting Abstract Oncology

LKB1 Mutations in Metastatic Non-Small Cell Lung Cancer (mNSCLC): Prognostic Value in the Real World

A. Golozar et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

Shunsuke Kitapma et al.

CANCER DISCOVERY (2019)

添加到收藏夹

Article Oncology

T Cell Dysfunction in Cancer

Daniela S. Thommen et al.

CANCER CELL (2018)

添加到收藏夹

Article Oncology

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma

Jerome Biton et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Immunology

The Immune Landscape of Cancer

Vesteinn Thorsson et al.

IMMUNITY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Perturbation-response genes reveal signaling footprints in cancer gene expression

Michael Schubert et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Article Oncology

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang et al.

NATURE MEDICINE (2018)

添加到收藏夹

Meeting Abstract Oncology

Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L) 1 Blockade in Patients with NSCLC Despite High TMB

K. Arbour et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer et al.

LANCET (2017)

添加到收藏夹

Article Oncology

Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies

Marco Mina et al.

CANCER CELL (2017)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher et al.

LANCET (2016)

添加到收藏夹

Review Oncology

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Geoffrey T. Gibney et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Ferdinandos Skoulidis et al.

CANCER DISCOVERY (2015)

添加到收藏夹

Review Immunology

Type I interferons in anticancer immunity

Laurence Zitvogel et al.

NATURE REVIEWS IMMUNOLOGY (2015)

添加到收藏夹

Article Oncology

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT

Jacob M. Kaufman et al.

JOURNAL OF THORACIC ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

S. Dearden et al.

ANNALS OF ONCOLOGY (2013)

添加到收藏夹

Article Biochemical Research Methods

GSVA: gene set variation analysis for microarray and RNA-Seq data

Sonja Haenzelmann et al.

BMC BIOINFORMATICS (2013)

添加到收藏夹

Review Oncology

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

David B. Shackelford et al.

NATURE REVIEWS CANCER (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.